Text Size

Systemic expression of Alu RNA in patients with geographic atrophy secondary to age-related macular degeneration

Yoshida H., Matsushita T., Kimura E., Fujita Y., Keany R., Ikeda T., Toshimori M., Imanaka T., Nakamura M.


  • 2019
  • PLoS ONE
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Other

  • Affiliations

    Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Research and Development Division, Santen Inc., Emeryville, CA, United States

Related Publications

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.


Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.


Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II/III ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y, on behalf of the ORANGE study investigators


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022